Influence of temperature on solvent-mediated anhydrate-to-hydrate transformation kinetics

Pharmaceutical Research

Volumn 28, Issue 2, 2011, Pages 364-373

  Qu, Haiyan ^a,b   Munk, Tommy ^a   Cornett, Claus ^a   Wu, Jian X ^a   Bøtker, Johan P ^a   Christensen, Lars P ^b   Rantanen, Jukka ^a   Tian, Fang ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

anhydrate to hydrate; crystallization; phase transformation; supersaturation

Indexed keywords

ANHYDRATE; CARBAMAZEPINE; CHEMICAL COMPOUND; HYDRATE; PIROXICAM; SOLVENT; UNCLASSIFIED DRUG;

ACCELERATION; ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DECELERATION; DRUG STRUCTURE; PHASE TRANSITION; PHYSICAL PARAMETERS; PRIORITY JOURNAL; RAMAN SPECTROMETRY; SOLUBILITY; SUPERSATURATION; TEMPERATURE; THERMODYNAMICS;

CARBAMAZEPINE; CRYSTALLIZATION; DRUG STABILITY; KINETICS; MODELS, CHEMICAL; PHASE TRANSITION; PIROXICAM; SOLUBILITY; SOLVENTS; SPECTRUM ANALYSIS, RAMAN; TECHNOLOGY, PHARMACEUTICAL; TEMPERATURE; THERMODYNAMICS;

EID: 79952489425     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0281-9     Document Type: Article

References (28)

1. Morris KR. Structural aspects of hydrates and solvates. In: Brittain HG, editor. Polymorphism in pharmaceutical solids. New York: Marcel Dekker, Inc; 1999. p. 125-81.
2. Kobayashi Y, Ito S, Itai S, Yamamoto K. Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate. Int J Pharm. 2000;193:137-45.
3. Grant DJW, Higuchi T. Solubility behavior of organic compounds. New York: Willey; 1990.
4. Qu H, Louhi-Kultanen M, Rantanen J, Kallas J. Solvent-mediated phase transformation kinetics of an anhydrate/hydrate system. Cryst Growth Des. 2006;6:2053-60. (Pubitemid 44450336)
5. Chiarella RA, Gillon AL, Burton RC, Davey RJ, Sadiq G, Auffret A, et al. The nucleation of inosine: the impact of solution chemistry on the appearance of polymorphic and hydrated crystal forms. Faraday Discuss. 2007;136:179-93.
6. Luk C-WJ, Rousseau RW. Solubilities of and transformations between the anhydrous and hydrated forms of L-serine in water-methanol solutions. Cryst Growth Des. 2006;6:1808-12. (Pubitemid 44320179)
7. Cardewand PT, Davey RJ. The kinetics of solvent-mediated phase transformations. Proc R Soc Lond A. 1985;398:415-28.
8. Daveyand RJ, Cardew PT. Rate controlling processes in solvent-mediated phase transformations. J Cryst Growth. 1986;79:648-53.
9. Wikström H, Kakidas C, Taylor LS. Determination of hydrate transition temperature using transformation kinetics obtained by Raman spectroscopoy. J Pharm Biomed Anal. 2009;49:247-52.
10. Krahn FU, Mielck JB. Relations between several polymorphic forms and the dihydrate of carbamazepine. Pharm Acta Hel. 1987;62:247-54. (Pubitemid 18073853)
11. Rustichelli C, Gamberini G, Ferioli V, Gamberini MC, Ficarra R, Tommasini S. Solid-state study of polymorphic drugs: carbamazepine. J Pharm Biomed Anal. 2000;23:41-54. (Pubitemid 30394550)
12. Reboul PJ, Cristau B, Soyfer JC. 5H-Dibenz[b, f]azepine-5-carboxamide (carbamazepine). Acta Crystallogr. 1981;B37:1844-8.
13. Mihalic M, Hofman H, Kajfez F, Kuftinec J, Blazvic N, Zinic M. Physico-chemical and analytical characteristics of piroxicam. Acta Pharm Jugosl. 1982;32:13-20. (Pubitemid 12145324)
14. Vrecer F, Vrbinc M, Meden A. Characterization of piroxicam crystal modifications. Int J Pharm. 2003;256:3-15. (Pubitemid 36412135)
15. Reck G, Dietz G, Laban G, Günther W, Bannier G, Höhne E. X-ray studies on piroxicam modifications. Pharmazie. 1988;43:477-81.
16. Qu H, Louhi-Kultanen M, Kallas J. Solubility and stability of anhydrate/hydrate in solvent mixtures. Int J Pharm. 2006;321:101-7. (Pubitemid 44247419)
17. Reck G, Dietz G. The order-disorder structure of carbamazepine dihydrate: 5H-dibenz [b, f] azepine-5-carboxamide dihydrate, C15H12N2O. Cryst Res Technol. 1986;21:1463-8.
18. Wu JX, Tian F, Cornett C, Munk T, Savolainen M, Rantanen J. Building a robust quantitative model for process monitoring of solid state transformation AAPS Annual meeting Nov 8-12. USA: Los Angeles; 2009.
19. Jennrich RI, Ralston ML. Fitting nonlinear models to data. Ann Rev Biophys Bioeng. 1979;8:195-238.
20. Draper NR, Smith H. Applied regression analysis, Wiley, ISBN: 0-471-02995-5, 1981.
21. Shefter E, Higuchi T. Dissolution behavior of crystalline solvated and nonsolvated forms of some pharmaceuticals. J Pharm Sci. 1963;52:781-91.
22. Grant DJW, Mehdizadeh M, Chow AHL, Fairbrother JE. Nonlinear van't Hoff solubility-temperature plots and their pharmaceutical interpretation. Int J Pharm. 1984;18:25-38. (Pubitemid 14184783)
23. Otsuka M, Teraoka R, Matsuda Y. Rotating-disk dissolution kinetics of nitrofurantoin anhydrate and monohydrate at various temperatures. Pharm Res. 1992;9:307-11.
24. Gu C-H, Grant DJW. Estimating the relative stability of polymorphs and hydrates from heats of solution and solubility data. J Pharm Sci. 2001;90:1277-87. (Pubitemid 32867976)
25. Wikström H, Rantanen J, Gift AD, Taylor LS. Towards an understanding of the factors influencing anhydrate-to-hydrate transformation kinetics in aqueous environments. Cryst Growth Des. 2008;8:2684-93.
26. Davey RJ, Blagden N, Righini S, Alison H, Ferrari ES. Nucleation control in solution mediated polymorphic phase transformations: the case of 2, 6-Dihydroxybenzoic acid. J Phys Chem B. 2002;106:1954-9. (Pubitemid 35276018)
27. Mullin JW. Crystallization. Oxford: Butterworth-Heinemann; 2001.
28. Mersmann A. Crystallization technology handbook. New York: Marcel Dekker; 2001.